Post-Bristol/Myers buyout, the IFM team lines up $31M to tackle a troika of NLRP3 targets
After years of lab work, the NLRP3 inflammasome has emerged as a prominent drug target in the biopharma world.
Just weeks after the UK’s NodThera launched to create new inhibitors for NLRP3, the team at IFM has rounded up $31 million to work on new drugs that could play a range of roles in fibrosis and errant immune responses linked to a medley of ailments, including neurodegenerative diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
